Company intelligence / Profile preview

InocuJect

Quebec City, Quebec, Canadalinkedin.com ↗

Ownership: Private
Development stage: Other

Overview

InocuJect has developed an electromechanical intradermal injection device designed to deliver vaccines painlessly and efficiently into the skin. The prototype is ready for preclinical testing at major research institutions. The technology claims over 100x improved immunization efficiency compared to traditional needle/syringe methods, with applications in both human and veterinary medicine. No published clinical results yet; initial proof-of-concept data referenced from academic publications by Dr. Gary Kobinger.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDNA vaccinemRNA-based drugs
Industry: Therapeutic Medical Devices

Partnerships

Testing partnerships with Galveston National Laboratory and Ottawa Hospital Research Institute; engineering collaboration with University Laval's engineering department

Beyond the preview

Go deeper on InocuJect.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InocuJect.

Explore the full profile